clinical trial · NCT07542483
A Study of Lebrikizumab in Adults With Nummular Eczema
Almirall, S.A.·phase3·not yet recruiting·n = 270
Nummular EczemaLebrikizumabPlacebo
brief summary
The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.
started
Apr 1, 2026
primary completion
Aug 1, 2028
completion
Feb 1, 2029
last updated
May 14, 2026
official title
A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema Who Are Not Adequately Controlled With Topical Corticosteroids or When This Treatment is Not Medically Advisable (LUMINE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol